Organoidsciences Ltd
Company Profile
Business description
Organoidsciences Ltd is a biotechnology company specializing in organoid technology, developing regenerative therapeutics and drug discovery solutions based on three-dimensional organoids. Its business includes ATORM, an organoid-based regenerative therapeutics pipeline, and ODISEI, an organoid-based drug discovery platform. ATORM is a regenerative therapeutic pipeline leveraging organoids derived from various human tissues, including the intestine and salivary gland, to develop novel treatments for a wide range of diseases. ODISEI is an organoid-based drug discovery solution that utilizes disease-specific organoids-including tumor, viral infection, intestinal, and skin organoids-to predict and evaluate human biological responses.
Contact
338 Pangyo-ro
6th floor, Bundang-gu
Gyeonggi-do
Seongnam-si
KORT: +82 27072024
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
86
Stocks News & Analysis
stocks
Chart of the Week: CGT reform strengthens the case for dividend investing
stocks
Finding ASX opportunities in lofty market conditions
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,136.30 | 49.20 | -0.54% |
| CAC 40 | 8,408.27 | 50.51 | -0.60% |
| DAX 40 | 25,460.48 | 3.53 | -0.01% |
| Dow JONES (US) | 51,594.14 | 1,153.18 | -2.19% |
| FTSE 100 | 10,908.41 | 37.39 | 0.34% |
| HKSE | 25,807.92 | 497.07 | 1.96% |
| NASDAQ | 24,442.94 | 433.97 | -1.74% |
| Nikkei 225 | 62,329.08 | 894.89 | 1.46% |
| NZX 50 Index | 13,786.62 | 190.05 | -1.36% |
| S&P 500 | 7,316.15 | 112.63 | -1.52% |
| S&P/ASX 200 | 8,981.20 | 43.60 | -0.48% |
| SSE Composite Index | 3,827.59 | 0.88 | -0.02% |